What is ex vivo receptor occupancy? Ex vivo receptor occupancy quantifies the percentage of target receptors occupied by a drug in tissue harvested from dosed animals. It uses quantitative autoradiography to provide direct evidence of target engagement with regional anatomical resolution, bridging in vitro binding affinity to in vivo drug action.
A recurring problem in drug discovery is that in vitro potency does not automatically translate into in vivo target engagement. A compound may bind its target with nanomolar affinity in a cell-free assay but still fail to engage the target at tolerated doses. Bioavailability, tissue distribution, plasma protein binding, blood-brain barrier penetration, metabolism, and competition with endogenous ligand can all break the link between affinity and effect. Ex vivo receptor occupancy (RO) studies address that gap directly.
The Principle
Animals are dosed with the test compound by the relevant route. At a defined post-dose interval, the tissue of interest, most commonly brain, is rapidly harvested. Cryosections are then incubated with a radioligand selective for the target receptor. Where the test compound remains bound, the radioligand is displaced. The percentage reduction in specific binding relative to vehicle controls is the receptor occupancy.
The readout is quantitative autoradiography using tritiated or iodinated radioligands exposed to phosphorimaging plates. Calibrated standards convert optical density to absolute binding values (fmol/mg tissue equivalent), providing quantitative occupancy with regional resolution.
Why Ex Vivo Occupancy Matters
First, it confirms target engagement in tissue. A compound with high in vitro affinity may fail to reach its target at sufficient concentrations in vivo. Ex vivo RO is a direct readout of whether the drug is where it needs to be.
In practice, receptor occupancy is often where a good in vitro molecule either starts to look doseable or starts to fall apart.
Second, it enables dose-occupancy modelling. By running RO across a dose range, the relationship between exposure and occupancy can be defined. For antipsychotics, D2/D3 occupancy between 65% and 80% is associated with therapeutic efficacy; above 80% the risk of extrapyramidal side effects increases. This principle, established through clinical PET, can be explored preclinically using ex vivo autoradiography.
Third, it provides regional resolution. Receptor density varies across brain structures. Ex vivo autoradiography measures occupancy in striatum, hippocampus, cortex, thalamus, and cerebellum within the same animal, revealing whether engagement is uniform or regionally variable.
Linking Occupancy to Functional Endpoints
The data become much more useful when occupancy is paired with pharmacokinetic and pharmacodynamic readouts from the same animals. Measuring plasma and brain drug concentrations alongside occupancy enables PK-RO models that show how exposure drives engagement over time. The vortioxetine programme is a good example: PET and ex vivo occupancy studies across species helped inform clinical dose selection, as reviewed by Varrone et al. (2022).
Practical Design Considerations
Radioligand choice drives the assay. It needs to be selective, have enough specific activity for autoradiographic detection, and bind a pharmacologically relevant site. The post-dose sacrifice time point should be guided by the compound’s pharmacokinetic profile, typically at or near Tmax for single-timepoint studies. Tissue processing must be rapid, with brain snap-frozen and cryosectioned at 10 to 20 micrometres.
Controls cannot be an afterthought. Vehicle-treated animals define control specific binding. Animals treated with a saturating dose of a known selective ligand help define non-specific binding and assay window. Where possible, plasma and brain sampling for PK analysis should be included.
Advantages Over Preclinical PET
While clinical PET is the gold standard in humans, preclinical PET in rodents is limited by spatial resolution, cost, and the requirement for positron-emitting radioligands. Ex vivo autoradiography uses tritiated or iodinated radioligands, gives high spatial resolution, allows multiple targets to be assessed in adjacent sections from the same animal, and does not require cyclotron access.
Multi-Target Occupancy and Peripheral Applications
A significant advantage of ex vivo autoradiography over PET is the ability to assess occupancy at multiple receptor targets in adjacent tissue sections from the same animal. A compound intended to act at both D2 and 5-HT2A receptors, for example, can have occupancy at both targets quantified simultaneously in striatal and cortical sections. This multi-target approach is directly relevant for atypical antipsychotics and multimodal antidepressants where the therapeutic profile depends on balanced engagement across several receptors.
Ex vivo occupancy is not limited to CNS targets. Peripheral tissues including heart, lung, gut, and spinal cord can be processed in the same way, providing occupancy data for targets expressed outside the brain. For oncology programmes targeting tumour-associated receptors, or for cardiovascular compounds acting at adrenergic or angiotensin receptors, the same autoradiographic methodology applies. The technique is target-agnostic; it requires only a selective radioligand and tissue expressing the receptor of interest.
Ex Vivo Occupancy at Gifford Bioscience
At Gifford Bioscience, ex vivo receptor occupancy is a core service. We process brain tissue from dosed animals, generate cryosections across defined regions, and perform quantitative autoradiography with validated radioligands. We work across species and targets, including monoamine receptors, GABAA subtypes, glutamate receptors, and orphan GPCRs. Where useful, we pair occupancy data with binding pharmacology from the same receptor system.
To discuss how Gifford Bioscience can support your programme, visit www.giffordbioscience.com or contact us at info@giffordbioscience.com.
Frequently Asked Questions
What is the difference between receptor occupancy and target engagement?
Target engagement confirms that a drug interacts with its intended biological target in vivo, while receptor occupancy goes a step further by quantifying the percentage of available receptors occupied by the compound. Ex vivo receptor occupancy therefore provides a quantitative measure of target engagement within specific tissues and anatomical regions.
How is ex vivo receptor occupancy measured?
Ex vivo receptor occupancy is commonly measured using quantitative autoradiography. Tissue is collected from animals following compound administration, cryosectioned and incubated with a selective radioligand. Reduced radioligand binding compared with vehicle-treated controls indicates that receptors remain occupied by the test compound, allowing percentage occupancy to be calculated.
How can receptor occupancy data help with dose selection?
Measuring receptor occupancy across several doses can establish the relationship between drug exposure and target engagement. When combined with pharmacokinetic and pharmacodynamic data, this can help identify the dose and exposure required to achieve a desired level of receptor occupancy and support the selection of doses for subsequent preclinical or clinical studies.
Is ex vivo receptor occupancy only suitable for CNS drug discovery?
Although ex vivo receptor occupancy is particularly valuable for CNS programmes because it can assess drug penetration and engagement across different brain regions, the technique can also be applied to peripheral tissues. These may include heart, lung, gut, spinal cord and tumour tissue, provided that a suitable selective radioligand is available for the target.
What are the advantages of ex vivo receptor occupancy over preclinical PET?
Ex vivo autoradiography can provide substantially higher spatial resolution than small-animal PET and can use tritiated or iodinated radioligands without requiring access to a cyclotron. It also allows different receptor targets to be analysed in adjacent tissue sections from the same animal, making it particularly useful for multi-target pharmacology and regional receptor occupancy studies.
References
- Wadenberg MLG, et al. Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology. 2000;150(4):422-429.
- Kapur S, et al. Relationship between dopamine D2 occupancy, clinical response, and side effects. Am J Psychiatry. 2000;157(4):514-520.
- Varrone A, et al. PET as a translational tool in drug development for neuroscience compounds. Clin Pharmacol Ther. 2022;111(4):774-785. doi:10.1002/cpt.2548.
- Jesudason CD, et al. In vivo receptor occupancy in rodents by LC-MS/MS. In: Assay Guidance Manual. NCATS; 2017.
- Farde L, et al. PET analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry. 1992;49(7):538-544.
- Langlois X, te Riele P, Wintmolders C, Leysen JE, Jurzak M. Use of the beta-imager for rapid ex vivo autoradiography exemplified with central nervous system penetrating neurokinin 3 antagonists. J Pharmacol Exp Ther. 2001;299(2):712-717.
- Bird MF, et al. MOP and NOP receptor interaction: Studies with a dual expression system and bivalent peptide ligands. PLoS ONE. 2022;17(1):e0260880.